Publications by authors named "Michael Youle"

Claim this Profile
A
Attenuated humoral responses in HIV after SARS-CoV-2 vaccination linked to B cell defects and altered immune profiles.
Emma Touizer, Aljawharah Alrubayyi, Rosemarie Ford, Noshin Hussain, Pehuén Pereyra Gerber, Michael Youle

iScience· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Attenuated humoral responses in HIV infection after SARS-CoV-2 vaccination are linked to global B cell defects and cellular immune profiles.
Emma Touizer, Aljawharah Alrubbayi, Rosemarie Ford, Noshin Hussain, Pehuén Pereyra Gerber, Michael Youle

bioRxiv· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals.
Alessandro Schipani, Christoph Wyen, Tabitha Mahungu, Heidy Hendra, Deirdre Egan, Michael Youle

J Antimicrob Chemother· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.
Joseph J Eron, Benjamin Young, David A Cooper, Michael Youle, Edwin Dejesus

Lancet· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A step ahead on the HIV collaboratory.
Robert L Murphy, Brigitte Autran, Christine Katlama, Gilles Brucker, Patrice Debre, Michael Youle

Science· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prescribing and using self-injectable antiretrovirals: how concordant are physician and patient perspectives?
Robert Horne, Colin Kovacs, Christine Katlama, Bonaventura Clotet, Carmina R Fumaz, Michael Youle

AIDS Res Ther· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection.
Clare L Booth, Ana M Garcia-Diaz, Michael S Youle, Margaret A Johnson, Andrew Phillips

J Antimicrob Chemother· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selected topics from the 10th Conference on Retroviruses and Opportunistic Infections.
Charles Hicks, Julio S G Montaner, Ronald Baker, Michael Youle

HIV Clin Trials· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Theoretical rationale for the use of sequential single-drug antiretroviral therapy for treatment of HIV infection.
Andrew N Phillips, Michael S Youle, Fiona Lampe, Margaret Johnson, Caroline A Sabin

AIDS· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression.
Andrew N Phillips, Schlomo Staszewski, Fiona Lampe, Michael S Youle, Stephan Klauke

J Infect Dis· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD4 cell count changes in individuals with counts above 500 cells/mm and viral loads below 50 copies/ml on antiretroviral therapy.
Andrew N Phillips, Michael Youle, Fiona Lampe, Caroline A Sabin, Andrew Hill

AIDS· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis